Aquadex SmartFlow®
Fluid Overload in Heart Failure (Adults)
Key Facts
About Nuwellis
Nuwellis is a commercial-stage medtech company with a mission to intervene earlier in cardiorenal disease progression through its proprietary, precision ultrafiltration technology. Its core achievement is the commercialization of the Aquadex SmartFlow® system, which is supported by over two decades of clinical evidence demonstrating reductions in hospitalizations, readmissions, and patient complications. The company's strategy focuses on expanding utilization of its single-platform technology across multiple clinical specialties—including heart failure, critical care, and pediatrics—by driving clinical education, securing reimbursement, and demonstrating cost-effectiveness to healthcare systems.
View full company profileAbout Nuwellis
Nuwellis is a commercial-stage medtech company with a mission to intervene earlier in cardiorenal disease progression through its proprietary, precision ultrafiltration technology. Its core achievement is the commercialization of the Aquadex SmartFlow® system, which is supported by over two decades of clinical evidence demonstrating reductions in hospitalizations, readmissions, and patient complications. The company's strategy focuses on expanding utilization of its single-platform technology across multiple clinical specialties—including heart failure, critical care, and pediatrics—by driving clinical education, securing reimbursement, and demonstrating cost-effectiveness to healthcare systems.
View full company profileAbout Nuwellis
Nuwellis is a commercial-stage medtech company with a mission to intervene earlier in cardiorenal disease progression through its proprietary, precision ultrafiltration technology. Its core achievement is the commercialization of the Aquadex SmartFlow® system, which is supported by over two decades of clinical evidence demonstrating reductions in hospitalizations, readmissions, and patient complications. The company's strategy focuses on expanding utilization of its single-platform technology across multiple clinical specialties—including heart failure, critical care, and pediatrics—by driving clinical education, securing reimbursement, and demonstrating cost-effectiveness to healthcare systems.
View full company profileAbout Nuwellis
Nuwellis is a commercial-stage medtech company with a mission to intervene earlier in cardiorenal disease progression through its proprietary, precision ultrafiltration technology. Its core achievement is the commercialization of the Aquadex SmartFlow® system, which is supported by over two decades of clinical evidence demonstrating reductions in hospitalizations, readmissions, and patient complications. The company's strategy focuses on expanding utilization of its single-platform technology across multiple clinical specialties—including heart failure, critical care, and pediatrics—by driving clinical education, securing reimbursement, and demonstrating cost-effectiveness to healthcare systems.
View full company profile